APX005M in Patients With Recurrent Ovarian Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 7, 2023

Primary Completion Date

September 7, 2023

Study Completion Date

September 7, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

APX005M

adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.

Trial Locations (1)

2100

NSGO-CTU, Copenhagen

Sponsors
All Listed Sponsors
collaborator

Belgian Gynaecological Oncology Group

OTHER

collaborator

GSO Global Clinical Research BV

OTHER

collaborator

The Central and Eastern European Gynecologic Oncology Group

OTHER

collaborator

Swiss GO Trial Group

NETWORK

lead

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

OTHER